• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 11Continence with 60 mg once daily of trospium vs. placebo in obese and nonobese adults with overactive bladder (pooled results from RCTs using the WHO criteria for obesity)553

Baseline body mass indexDrug events/ randomizedPlacebo events/ randomizedRate (%) in active/ controlRelative risk (95% CI)Absolute risk difference (95% CI)Number needed to treat (95% CI)Attributable events per 1,000 treated (95% CI)
BMI <30kg/m2214/578133/57837/231.6(1.3 to 1.9)0.14(0.09 to 0.19)7 (5 to 11)140(88 to 192)
BMI <35kg/m2202/578133/57835/231.5(1.3 to 1.8)0.12(0.07 to 0.17)8 (6 to 15)119(68 to 171)
BMI >30kg/m2191/578127/57833/221.5(1.2 to 1.8)0.11(0.06 to 0.16)9 (6 to 17)111(60 to 162)
BMI >35kg/m2202/578121/57835/211.7(1.4 to 2.0)0.14(0.09 to 0.19)7 (5 to 11)140(89 to 191)

From: Results

Cover of Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness
Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness [Internet].
Comparative Effectiveness Reviews, No. 36.
Shamliyan T, Wyman J, Kane RL.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.